Chester County Gene Therapy Firm Fibrocell Science Makes Pitch To Investors


With a trio of potential solutions for rare skin diseases being studied or soon to be studied on humans, an Exton research firm took the stage during RegenMed Investor Day in New York City to try to apply another coat of funding to the effort.

Fibrocell Science Vice President of Scientific Affairs John Maslowski introduced and fielded questions from investors about his company’s prospective gene therapies, the skin conditions they aim to treat and the expectations for in-process and upcoming Phase II clinical studies, according to a video published by gene therapy news portal IPS Cell Therapy.

Fibrocell Science focuses on developing skin disease gene therapies for rare pediatric and other diseases based on the platform of the autologous fibroblast cell, which creates a structural framework for connective tissue. Fibrocell is using autologous fibroblasts to be internal protein factories where such structural frameworks are missing or inadequate.

Among its leading research prospects are treatments for vocal cord scarring, which is currently being studied in a Phase II clinical trial; for Recessive Dystrophic Epidermolysis Bullosa (RDEB) disease, which is being co-developed with Intrexon to produce an investigative new drug application by mid-year; and for linear scleroderma, also being co-developed with Intrexon to produce an IND application in 2016.

Watch Maslowski make his investment pitch and explain Fibrocell’s process and clinical study plans in IPS Cell Therapy here.

Connect With Your Community

Subscribe to stay informed!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.